Clinical Trial

A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA)

Name: A Phase II Study of Ivonescimab Combined With Intraperitoneal Paclitaxel in Patients With High-Grade Metastatic Appendiceal Adenocarcinoma (AA) — clinical trial record (NCT07753824)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

To evaluate the safety and effectiveness of Ivonescimab combined with intraperitoneal paclitaxel (IP PTX) in patients with unresectable metastatic high-grade Appendiceal Adenocarcinoma (AA).

Trial Details

NCT Number	NCT07753824
Lead Sponsor	M.D. Anderson Cancer Center Collaborators: Cancer Prevention Research Institute of Texas, Summit Therapeutics
Conditions	Phase II, Ivonescimab, Intraperitoneal, Paclitaxel, High Grade Metastatic, Appendiceal Adenocarcinoma
Enrollment	30 participants
Start Date	2027-01-16
Primary Completion	2031-11-28 (estimated)
Study Completion	2032-11-28 (estimated)
Updated on ClinicalTrials.gov	2026-08-10